红乌合剂联合化疗对晚期食管癌患者近期疗效及生存质量的影响

目的研究红乌合剂联合化疗在晚期食管癌治疗中的疗效。方法选取47例晚期食管癌患者,分为治疗组(24例,红乌合剂联合化疗组)与对照组(23例,单纯化疗组),21 d为1个周期,2个周期后观察临床疗效。结果在近期疗效方面,治疗组有效率为50.0%,疾病控制率为87.5%;对照组有效率为30.4%,疾病控制率为60.9%。两组间有效率比较无统计学意义(P0.05),两组疾病控制率比较差异显著(P0.05)。生存质量评分方面,在躯体、情绪、总生存质量及疼痛方面,两组比较差异显著(P0.05)。毒副反应方面,两组比较差异不显著(P0.05)。结论红乌合剂联合化疗治疗晚期食管癌可提高化疗疗效、改善患者生存质量,且未增加毒副反应,安全可靠。

Research on short term efficacy and quality of life in treatment of advanced esophageal cancer with Hongwu Mixture in combination with chemotherapy

Objective To research the efficacy in the treatment of advanced esophageal cancer with Hongwu Mixture in combination with chemotherapy. Methods Forty-seveb advanced esophageal cancer patients were admitted, then were divided into two groups, one was the treatment group (24 cases, Hongwu Mixture combined with chemotherapy), and the other was the control group (23 cases, chemotherapy alone). After two cycles treatment, the clinical efficacy was observed. Results In the short team efficacy, the effective rate in the treatment group was 50.0% and the disease control rate was 87.5%, while these rates were 30.4% and 60.9% respectively in the control group. The difference of the effective rate between the two groups was no statistically significant (P > 0.05); But the difference of the disease control rate was statistically significant (P < 0.05). In the scores of quality of life, the difference of the physical, emotional, overall quality of life and pain between e two groups were statistically significant (P < 0.05). Toxic and side effects between two groups were no statistically significant (P > 0.05). Conclusion The treatment of Hongwu Mixture combined with chemotherapy in advanced esophageal cancer can improve the efficacy of chemotherapy and the quality of life. Moreover, it is safe and reliable without enhancing the toxic and side effects.